Navigation Links
Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival

DE as an important therapy for front-line patients."

The multi-center, randomized Phase III trial is being conducted by the IFM cooperative group. The trial was designed to compare VELCADE in combination with dexamethasone to VAD as induction therapy prior to SCT in 480 newly diagnosed MM patients. The presentation during IMW included new data from 161 patients who received induction therapy, of which 137 patients received SCT. Results presented by Dr. Harousseau showed:

     * As induction therapy prior to SCT, the VELCADE based therapy showed

       a CR rate of 20 percent compared to 7 percent for VAD.

     * Following SCT, the VELCADE based therapy demonstrated a CR rate of

       43 percent and a very good partial response + CR (VGPR + CR) rate of 75

       percent.  VAD showed a CR rate of 28 percent and a VGPR + CR

       rate of 46 percent following SCT.

     * The VELCADE based therapy was well tolerated; the most common adverse

       events included neurologic toxicities, fever/infection and neutropenia.

Patients on the VELCADE based therapy received four standard cycles of VELCADE at 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21-day cycle. Patients also received dexamethasone at 40 mg on days 1 through 4 during cycles one through four and on days 9 through 12 during cycles one and two only. Patients on VAD were treated for four cycles with vincristine at 0.4 mg/m2 on days 1 through 4; adriamycin at 9 mg/m2 on days 1 through 4; and dexamethasone 40 mg on days 1 through 4, days 9 through 12 during cycles one through four and on days 17 through 20 during cycles one and two only. Some patients received consolidation therapy. Response was assessed by the European Group for Blood and Marrow Transplant criteria.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), r
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

Post Your Comments:
(Date:11/6/2009)...Nov. 6 GeoVax Labs, Inc...mpany"), an Atlanta-based, biopharmaceutical compa...y HIV-1 (Human Immunodeficiency Virus) and other i...r 2009 financial results and provided an operation...and Chief Executive Officer commented, "We are ple...
(Date:11/6/2009)..., November 6 , - Trial Wi...d for the,Treatment of Multi-Resistant Staphylococ... speciality pharmaceutical company focused on the ...igned to overcome the significant global,problem o...ost advanced oral,antibacterial NXL103 (flopristin...
(Date:11/5/2009)...ntario, Nov. 5 Helix Bio...unced today that its Phase II trial of Topical Int...warts (AGW) has completed patient enrollment, with...e trial. ,, The double-blind and placebo-contro...s in Germany and Sweden. Patients participating i...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Nanoparticle delivered 26apos 3BSuicide 26apos 3B Genes Slowed Ovarian Tumor Growth 53171 1Nanoparticle delivered 26apos 3BSuicide 26apos 3B Genes Slowed Ovarian Tumor Growth 53171 2Nanoparticle delivered 26apos 3BSuicide 26apos 3B Genes Slowed Ovarian Tumor Growth 53171 3First genetically engineered malaria vaccine to enter human trials 13267 1First genetically engineered malaria vaccine to enter human trials 13267 2U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 1U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 2U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 3U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 4
(Date:11/8/2009)...s House Passage of Health Care Reform Bill ,, ...mprove coverage for all Americans ,, CHICAGO, ...d States House of Representatives passed by a vote...on that would strengthen Medicare for seniors and ...ces millions of Americans out of affordable health...
(Date:11/7/2009)...Nov. 7 Karen Ignagni, P...ns (AHIP), released the following statement today ... strongly support comprehensive health care reform...oposing a complete overhaul of how health insuranc...anteed coverage, elimination of pre-existing condi...
(Date:11/7/2009).... Coleman (CT), David A. Cook (GA), Louis J. Goodm...) Honored ,, CHICAGO, Nov. 7 /PRNewswire-USNew...oday presented five medical society executive lead...utions to the goals and ideals of the medical prof...i-annual policy making meeting in Houston. ,, ...
(Date:11/7/2009)...ithful Catholics have a responsibility to vigorous...e status quo." ,, WASHINGTON, Nov. 7 /PRNew...nt Judie Brown released the following statement on... Speaker Nancy Pelosi,s Affordable Health Care for...eserving the status quo for abortion is voted upon...
(Date:11/7/2009)... The Public Relations Society of America (PRSA) wi...ne Gage Lofgren, senior vice president of Brand St...e, tonight at a ceremony at PRSA,s 2009 Internatio...into the PRSA College of Fellows is one of the pro... Herman, APR, SAGE, Fellow PRSA, and 2009 chair of...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3
...will benefit, SACRAMENTO, Calif., Oct. 10 The go... State University (CSU) retirees to,participate in... "We are very grateful that the Legislature and go...n people have good,vision care, they have a greate...
...y Health System (VHS),caregivers, members of SEIU ...whelmingly last week to endorse Measure G on the N...uled for Thursday, October 11th, 12:00pm, at,the s...t Valley Medical Center, Menifee Valley Medical Ce...
... Access to Affordable Health Insurance, ERIE, Pa....nians, the centerpiece of his "Prescription for Pe...vernor Edward G. Rendell today held a,town meeting...e. Erie County has more than 10,000 uninsured adul...
... in the U.S. may,be breathing its last gasps, with...n America Act this past week. It now moves on to t...cted to be imminent. Championed by,Senator Patty M...ng in developing effective treatment for Mesotheli...
...onal Medical,Association (NMA) announced the appoi...ternal Affairs., "Alisa has done a terrific job a...d members of the Board of Trustees along with me a...the Director of External Affairs, Ms. Mosley will ...
...ty with breast cancer who are given drugs in addit...vant chemotherapy, may not be benefiting from thes...espond to changing levels of hormones such as estr...erms of survival," explained lead researcher Dr J ...
Other Medicine News:Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2Health News:Valley Health System Caregivers, Members of SEIU UHW, to Announce Endorsement of Measure G 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 3Health News:A Breath of Fresh Air From Washington: Senate Passes Historic Asbestos Ban 2Health News:A Breath of Fresh Air From Washington: Senate Passes Historic Asbestos Ban 3Health News:Cancer conflict with chemotherapy treatment 2
Active Ankle Orthosis(Trainers)
Bledsoe M-Brace Ankle Support
Bledsoe Short Term Boot
Bledsoe Low Cost Boot
Medicine Products: